Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K-Reference-Cited by-同舟云学术

Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K

Published:2004-10-05 Issue:1 Volume:63 Page:44-55
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Gutiérrez-Cañas Irene,Juarranz María G.,Collado Beatriz,Rodríguez-Henche Nieves,Chiloeches Antonio,Prieto Juan C.,Carmena María J.

Funder

Ministerio de Ciencia y Tecnología

Asociación Española de Urología (Premio Leonardo de la Peña-Yamanouchi)

Publisher

Wiley

Subject

Urology,Oncology

Reference41 articles.

1. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells;Wright;Mol Endocrinol,2003

2. Neuroendocrine peptides in the prostate;Gkonos;Urol Res,1995

3. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer;Aprikian;Prostate,1998

4. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells;Bonkhoff;Hum Pathol,1995

5. Vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor subtypes in human tumors and their tissues of origin;Reubi;Cancer Res,2000

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization;Current Protein & Peptide Science;2024-07

2. Endocrine and paracrine characteristics of neuroendocrine prostate cancer;Frontiers in Endocrinology;2022-11-11

3. Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors;International Journal of Molecular Sciences;2022-07-22

4. Signal Transduction by VIP and PACAP Receptors;Biomedicines;2022-02-09

5. Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease;Peptide and Peptidomimetic Therapeutics;2022